Therapy of the respiratory distress syndrome.
D001833:Body Temperature Regulation; D002395:Catecholamines / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006706:Homeostasis; D006801:Humans; D006932:Hyperbilirubinemia / Q000209:etiology; D006996:Hypocalcemia / Q000209:etiology; D007022:Hypotension / Q000209:etiology; D007035:Hypothermia / Q000209:etiology; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D007647:Kernicterus / Q000209:etiology; D008991:Monitoring, Physiologic; D010100:Oxygen / Q000097:blood / Q000506:poisoning; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects; D010106:Oxygenators; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy / Q000628:therapy*; D012769:Shock / Q000517:prevention & control; D014043:Tolazoline / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D012122:Ventilators, Mechanical; D014882:Water-Electrolyte Balance
D002395:Catecholamines; D005343:Fibrinolytic Agents; D006634:Histamine H1 Antagonists; D014665:Vasodilator Agents; D014043:Tolazoline; D010100:Oxygen